Track topics on Twitter Track topics that are important to you
Novo Nordisk has reported Phase III data that reveal its candidate semaglutide improved glucose control and weight loss in type 2 diabetes when compared with Eli Lilly’s dulaglutide. The results of the SUSTAIN 7 trial comparing the efficacy of Novo ...
This awesome article Novo Nordisk’s New Type 2 Diabetes Drug Outperforms Eli Lilly’s appeared first on Labiotech.eu. Be kind and don't copy it without asking ;)
Original Article: Novo Nordisk’s New Type 2 Diabetes Drug Outperforms Eli Lilly’sNEXT ARTICLE
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...